LIVER DISEASE: Injury to the liver (from infections, alcohol, tumors and fat buildup) leads to scar tissue (“fibrosis”) that can reduce liver function. However, the liver has the ability to regenerate thus mitigating the damage. The amount of liver function remaining is determined by the net effect of fibrogenesis and regeneration. It is the residual liver function that determines disease outcomes. Measuring fibrosis alone is not enough!

PRODUCT: The HEPATIQ® test measures liver function. This is essential for therapy planning and predicting adverse outcomes including liver transplantation. HEPATIQ provides 3 indices of disease severity - PHM®, fSV® and fLV®. These indices identify patients at risk for future decompensation, and patients with adequate hepatic reserve who would have benign outcomes. Patients with low PHM have a 15-fold increase in risk for hepatic decompensation or liver-related death.

VALIDATION: The PHM index was proven to predict clinical outcomes in the prospective 7-year multi-center HALT-C trial. PHM outperformed standard blood tests and liver biopsies in predicting clinical outcomes. PHM was also shown to track liver function regeneration after an adult-to-adult live donor liver transplant in the A2ALL study.

COMPETITION: Standard blood tests are affected by many factors and don't predict clinical outcomes.   The HALT-C trial showed that blood tests were normal in patients who later developed adverse outcomes. Liver biopsy measures fibrosis (not function), is invasive, costly, and subject to error as only a small piece of a large organ is sampled. Ultrasound based tests are also measuring fibrosis and not function!

HEPATIQ has been cleared by the FDA for sale in the U.S.A.

For a webinar on the clinical value of HEPATIQ, please contact:
      John Hoefs, MD.
      Chief Operating Officer